Back to Search
Start Over
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
- Source :
-
Medizinische Klinik, Intensivmedizin und Notfallmedizin [Med Klin Intensivmed Notfmed] 2017 Mar; Vol. 112 (2), pp. 145-148. Date of Electronic Publication: 2016 May 24. - Publication Year :
- 2017
-
Abstract
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are new antidiabetic drugs that regulate blood glucose levels by increasing urinary glucose excretion. In May 2015, the U.S. Food and Drug Administration (FDA) issued a warning that SGLT2 inhibitors may lead to ketoacidosis. In this report, we describe a case of life-threatening euglycemic ketoacidosis associated with SGLT2 inhibition and evaluate possible mechanisms and triggers.
- Subjects :
- Benzhydryl Compounds adverse effects
Benzhydryl Compounds therapeutic use
Combined Modality Therapy
Diabetic Ketoacidosis therapy
Drug Therapy, Combination
Glucosides adverse effects
Glucosides therapeutic use
Humans
Insulin Glargine adverse effects
Insulin Glargine therapeutic use
Male
Metformin adverse effects
Metformin therapeutic use
Middle Aged
Risk Factors
Sodium-Glucose Transporter 2
Blood Glucose metabolism
Diabetes Mellitus, Type 2 blood
Diabetes Mellitus, Type 2 drug therapy
Diabetic Ketoacidosis blood
Diabetic Ketoacidosis chemically induced
Hypoglycemic Agents adverse effects
Hypoglycemic Agents therapeutic use
Sodium-Glucose Transporter 2 Inhibitors
Subjects
Details
- Language :
- German
- ISSN :
- 2193-6226
- Volume :
- 112
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Medizinische Klinik, Intensivmedizin und Notfallmedizin
- Publication Type :
- Academic Journal
- Accession number :
- 27221094
- Full Text :
- https://doi.org/10.1007/s00063-016-0153-0